Cerevance Named Karl Kieburtz Chief Medical Officer
Boston-based Cerevance hired Karl Kieburtz to lead the Phase 3 clinical development of its Parkinson's therapy.
Updated on Oct. 5, 2026 in Alzheimer’s
Live Poll
Do you trust that new corporate leadership in medical companies leads to better patient outcomes?
Cerevance has appointed neurologist Karl Kieburtz as its new chief medical officer to oversee the ongoing development of its drug candidate, solengepras. Kieburtz, a professor at the University of Rochester, brings three decades of experience to the firm.
Why it matters
The appointment bolsters the company's efforts to advance solengepras, a once-daily oral therapy currently in Phase 3 trials for Parkinson's disease. The leadership change is intended to support the successful clinical progression of this potential GPR6 inhibitor.
Solengepras is currently being evaluated in the ARISE trial as an adjunctive treatment to levodopa, drawing on findings from the proprietary NETSseq platform. Kieburtz brings 3 decades of clinical trial expertise to the role.
The players
Karl Kieburtz
He is a professor of neurology at the University of Rochester and a co-founder of Clintrex Research LLC.
Cerevance
This Boston-based biotechnology company utilizes its proprietary NETSseq platform to identify novel drug targets from human brain tissue.
The details
Kieburtz, who previously served in an advisory capacity for the company, joins the leadership team to guide the drug through critical late-stage testing. Solengepras is designed as a non-dopaminergic therapy intended to reduce daily OFF time for Parkinson's patients.
Timeline
October 5, 2026: Cerevance announced the appointment of Karl Kieburtz.
The Big Picture
The appointment follows the pattern established by the ARISE trial, as Cerevance seeks to solidify its clinical leadership.
The progress of solengepras could eventually offer a new treatment option for patients seeking to manage daily OFF time in Parkinson's disease. Patients should monitor clinical trial updates for information on the drug's potential efficacy and availability.
The takeaway
The addition of an experienced medical lead highlights the importance of expert oversight in navigating the final stages of drug approval. Patients and their families should continue to rely on neurologists for guidance as new non-dopaminergic therapies progress through development.
Further reading
For more information on the latest research and clinical developments in this field, visit our Alzheimer’s section.
More information
For more information on the company's research pipeline, visit the Cerevance official company website.
Live Poll
Do you trust that new corporate leadership in medical companies leads to better patient outcomes?
